HC Wainwright Reiterates “Buy” Rating for uniQure (NASDAQ:QURE)

uniQure (NASDAQ:QURE)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $25.00 target price on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 236.47% from the stock’s previous close.

A number of other analysts have also weighed in on QURE. StockNews.com raised shares of uniQure to a “sell” rating in a research note on Thursday, October 17th. Raymond James reaffirmed an “outperform” rating and set a $20.00 price target on shares of uniQure in a research note on Thursday, October 10th. The Goldman Sachs Group dropped their price objective on uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a research note on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $28.00 target price on shares of uniQure in a report on Wednesday. Finally, Royal Bank of Canada cut their price target on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $17.00.

uniQure Stock Up 3.8 %

Shares of uniQure stock opened at $7.43 on Wednesday. The company has a debt-to-equity ratio of 1.06, a current ratio of 7.36 and a quick ratio of 7.36. uniQure has a 1-year low of $3.73 and a 1-year high of $11.35. The business’s fifty day moving average price is $5.73 and its two-hundred day moving average price is $5.80. The company has a market capitalization of $361.84 million, a P/E ratio of -1.25 and a beta of 0.90.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. The business had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative net margin of 1,027.52% and a negative return on equity of 158.09%. As a group, research analysts forecast that uniQure will post -4.1 EPS for the current year.

Hedge Funds Weigh In On uniQure

Institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in shares of uniQure by 11.4% in the first quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock worth $5,577,000 after buying an additional 109,740 shares during the period. Acadian Asset Management LLC boosted its stake in uniQure by 133.1% in the 1st quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock worth $3,189,000 after purchasing an additional 350,291 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in uniQure by 74.1% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 157,312 shares of the biotechnology company’s stock worth $818,000 after purchasing an additional 66,958 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in uniQure by 49.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 271,346 shares of the biotechnology company’s stock valued at $1,338,000 after purchasing an additional 89,400 shares during the period. Finally, BNP Paribas Financial Markets lifted its holdings in shares of uniQure by 4.3% in the first quarter. BNP Paribas Financial Markets now owns 736,724 shares of the biotechnology company’s stock valued at $3,831,000 after purchasing an additional 30,054 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.